494 related articles for article (PubMed ID: 18202762)
21. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.
Ferrario A; Rucker N; Wong S; Luna M; Gomer CJ
Cancer Res; 2007 May; 67(10):4989-95. PubMed ID: 17510430
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of oxygen consumption of culture medium and in vitro photodynamic effect of talaporfin sodium in lung tumor cells.
Tomioka Y; Kushibiki T; Awazu K
Photomed Laser Surg; 2010 Jun; 28(3):385-90. PubMed ID: 19860571
[TBL] [Abstract][Full Text] [Related]
23. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
24. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Ferrario A; Kessel D; Gomer CJ
Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
[TBL] [Abstract][Full Text] [Related]
25. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells.
Shen XY; Zacal N; Singh G; Rainbow AJ
Photochem Photobiol; 2005; 81(2):306-13. PubMed ID: 15560738
[TBL] [Abstract][Full Text] [Related]
26. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
27. Long-term regression of the murine mammary adenocarcinoma, LM3, by repeated photodynamic treatments using meso-tetra (4-N-methylpyridinium) porphine.
Colombo LL; Vanzulli SI; Villanueva A; Cañete M; Juarranz A; Stockert JC
Int J Oncol; 2005 Oct; 27(4):1053-9. PubMed ID: 16142323
[TBL] [Abstract][Full Text] [Related]
28. Studies on preparation and photodynamic mechanism of chlorin P6-13,15-N-(cyclohexyl)cycloimide (Chlorin-H) and its antitumor effect for photodynamic therapy in vitro and in vivo.
Yan YJ; Zheng MZ; Chen ZL; Yu XH; Yang XX; Ding ZL; Xu L
Bioorg Med Chem; 2010 Sep; 18(17):6282-91. PubMed ID: 20691601
[TBL] [Abstract][Full Text] [Related]
29. Changes in VEGF level and tumor growth characteristics during lewis lung carcinoma progression towards cis-DDP resistance.
Pyaskovskaya ON; Dasyukevich OI; Kolesnik DL; Garmanchouk LV; Todor IN; Solyanik GI
Exp Oncol; 2007 Sep; 29(3):197-202. PubMed ID: 18004244
[TBL] [Abstract][Full Text] [Related]
30. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398.
Harvey EH; Webber J; Kessel D; Fromm D
Am J Surg; 2005 Mar; 189(3):302-5. PubMed ID: 15792755
[TBL] [Abstract][Full Text] [Related]
31. Dying cells program their expedient disposal: serum amyloid P component upregulation in vivo and in vitro induced by photodynamic therapy of cancer.
Merchant S; Sun J; Korbelik M
Photochem Photobiol Sci; 2007 Dec; 6(12):1284-9. PubMed ID: 18046483
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and photobiological study of a novel chlorin photosensitizer BCPD-18MA for photodynamic therapy.
Zhang J; Deng L; Yao J; Gu P; Yang F; Wang X; Liu W; Zhang Y; Ke X; Jing X; Chen J
Bioorg Med Chem; 2011 Sep; 19(18):5520-8. PubMed ID: 21855352
[TBL] [Abstract][Full Text] [Related]
33. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency.
Jee SH; Shen SC; Chiu HC; Tsai WL; Kuo ML
Oncogene; 2001 Jan; 20(2):198-208. PubMed ID: 11313947
[TBL] [Abstract][Full Text] [Related]
35. New two-photon activated photodynamic therapy sensitizers induce xenograft tumor regressions after near-IR laser treatment through the body of the host mouse.
Starkey JR; Rebane AK; Drobizhev MA; Meng F; Gong A; Elliott A; McInnerney K; Spangler CW
Clin Cancer Res; 2008 Oct; 14(20):6564-73. PubMed ID: 18927297
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
37. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
38. mTHPC-mediated photodynamic treatment up-regulates the cytokines VEGF and IL-1alpha.
Dabkeviciene D; Sasnauskiene A; Leman E; Kvietkauskaite R; Daugelaviciene N; Stankevicius V; Jurgelevicius V; Juodka B; Kirveliene V
Photochem Photobiol; 2012; 88(2):432-9. PubMed ID: 22171990
[TBL] [Abstract][Full Text] [Related]
39. Fractionated photodynamic therapy for a human oral squamous cell carcinoma xenograft.
Togashi H; Uehara M; Ikeda H; Inokuchi T
Oral Oncol; 2006 May; 42(5):526-32. PubMed ID: 16466960
[TBL] [Abstract][Full Text] [Related]
40. Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes.
Maugain E; Sasnouski S; Zorin V; Merlin JL; Guillemin F; Bezdetnaya L
Oncol Rep; 2004 Sep; 12(3):639-45. PubMed ID: 15289849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
